MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.
MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.
复制标题
DOI：
10.1371/journal.pone.0107677
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Syrigos KN
中科院分区：
文献类型：
--
作者：
Dimou A;Non L;Chae YK;Tester WJ;Syrigos KN
MET是存在于NSCLC细胞膜中的受体，并且已知促进细胞增殖、存活和迁移。MET基因拷贝数是一种常见的基因改变，抑制MET成为NSCLC的一种有希望的靶向治疗。在此，我们的目标是在荟萃分析中联合收割机，高MET基因拷贝数对切除的NSCLC患者总生存率影响的数据。两名独立的研究者在PubMed中使用术语“MET和肺癌”、“MET和NSCLC”、“MET基因拷贝数和预后”应用平行检索策略，直至2014年1月。我们选择了研究MET基因拷贝数与接受手术患者生存率相关性的研究。在初始检索确定的1096个标题中，我们检索到9项关于回顾性队列的研究，这些研究具有关于MET基因拷贝数对NSCLC患者生存期的预后影响的充分可检索数据。其中，6例使用FISH，其余3例使用RT PCR评估原发肿瘤中的MET基因拷贝数。我们计算I2统计量以评估异质性（I2 = 72%）。 当所有研究在随机效应模型中合并时，MET基因拷贝数预测总生存率较差（HR = 1.78，95%CI 1.22-2.60）。 当仅纳入其人群中至少有50%腺癌患者的研究时，效果显著（5项研究，HR 1.55，95% CI 1.23-1.94）。当我们仅纳入腺癌组织学患者不超过50%的研究时，情况并非如此（4项研究HR 2.18，95% CI 0.97-4.90）。诊断时原发肿瘤中MET基因拷贝数较高预示NSCLC患者预后较差。这种预后影响可能是腺癌组织学特异性的。
MET is a receptor present in the membrane of NSCLC cells and is known to promote cell proliferation, survival and migration. MET gene copy number is a common genetic alteration and inhibition o MET emerges as a promising targeted therapy in NSCLC. Here we aim to combine in a meta-analysis, data on the effect of high MET gene copy number on the overall survival of patients with resected NSCLC. Two independent investigators applied parallel search strategies with the terms “MET AND lung cancer”, “MET AND NSCLC”, “MET gene copy number AND prognosis” in PubMed through January 2014. We selected the studies that investigated the association of MET gene copy number with survival, in patients who received surgery. Among 1096 titles that were identified in the initial search, we retrieved 9 studies on retrospective cohorts with adequate retrievable data regarding the prognostic impact of MET gene copy number on the survival of patients with NSCLC. Out of those, 6 used FISH and the remaining 3 used RT PCR to assess the MET gene copy number in the primary tumor. We calculated the I2 statistic to assess heterogeneity (I2 = 72%). MET gene copy number predicted worse overall survival when all studies were combined in a random effects model (HR = 1.78, 95% CI 1.22–2.60). When only the studies that had at least 50% of adenocarcinoma patients in their populations were included, the effect was significant (five studies, HR 1.55, 95% CI 1.23–1.94). This was not true when we included only the studies with no more than 50% of the patients having adenocarcinoma histology (four studies HR 2.18, 95% CI 0.97–4.90). Higher MET gene copy number in the primary tumor at the time of diagnosis predicts worse outcome in patients with NSCLC. This prognostic impact may be adenocarcinoma histology specific.
登录
查看更多内容
DOI：
10.1615/jenvironpatholtoxicoloncol.v28.i2.10
发表时间：
2009
期刊：
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
影响因子：
--
作者：
Kanteti R;Yala S;Ferguson MK;Salgia R
通讯作者：
Salgia R
影响因子：
3.7
作者：
Franci C;Zhou J;Jiang Z;Modrusan Z;Good Z;Jackson E;Kouros-Mehr H
通讯作者：
Kouros-Mehr H
DOI：
10.1158/1078-0432.ccr-11-1404
发表时间：
2011-12-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Sasaki T;Jänne PA
通讯作者：
Jänne PA
影响因子：
105.7
作者：
Sterne, Jonathan A. C.;Sutton, Alex J.;Higgins, Julian P. T.
通讯作者：
Higgins, Julian P. T.
DOI：
10.1158/1078-0432.ccr-09-0070
发表时间：
2009-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Krishnaswamy S;Kanteti R;Duke-Cohan JS;Loganathan S;Liu W;Ma PC;Sattler M;Singleton PA;Ramnath N;Innocenti F;Nicolae DL;Ouyang Z;Liang J;Minna J;Kozloff MF;Ferguson MK;Natarajan V;Wang YC;Garcia JG;Vokes EE;Salgia R
通讯作者：
Salgia R